Last reviewed · How we verify

NCT00535080

Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease

NO LONGER AVAILABLE Last updated 18 February 2021
What this trial tests

trial testing Metvix (methyl aminolevulinate) in Field Actinic Keratoses. No longer available.

Quick facts

Lead sponsorGalderma R&D
StatusNO LONGER AVAILABLE
Study typeEXPANDED_ACCESS

Drugs / interventions tested

Conditions studied

Sponsor

Galderma R&D — full company profile →

Who can join

18 and older, any sex, with Field Actinic Keratoses or Basal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to provide this investigational drug to patients who cannot be optimally treated with conventional therapies and to collect efficacy and safety data on the use of Metvix PDT in subjects with field actinic keratoses, large/multiple superficial basal cell carcinomas (BCCs) or Bowen's disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Galderma R&D trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00535080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing